Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial

Journal of Clinical Oncology

Volumn 34, Issue 6, 2016, Pages 581-587

  Advani, Pooja P ^a   Ballman, Karla V ^b   Dockter, Travis J ^b   Colon Otero, Gerardo ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; PACLITAXEL; TRASTUZUMAB; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; ETHNICITY; EVALUATION STUDY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; AGE; AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMISTRY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; RISK FACTOR; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIAS, CARDIAC; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; RECEPTOR, ERBB-2; RISK FACTORS; STROKE VOLUME; TRASTUZUMAB; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84964292383     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.8413     Document Type: Article

References (19)

1. Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6,556 breast cancer tissues. Clin Breast Cancer 5:63-69, 2004
2. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005
4. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
5. Perez EA, Romond EH, Suman VJ, et al: Fouryear follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
6. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of HER2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7:153, 2007
7. Perez EA, Romond EH, Suman VJ, et al: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: Planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744-3752, 2014
8. Russell SD, Blackwell KL, Lawrence J, et al: Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28:3416-3421, 2010
9. Chavez-MacGregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31: 4222-4228, 2013
10. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
11. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
12. Gray RJ: A class of K sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 16:1141-1154, 1988
13. De Azambuja E, Procter MJ, Van Veldhuisen DJ, et al: Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01). J Clin Oncol 32:2159-2165, 2014
14. Moja L, Tagliabue L, Balduzzi S, et al: Trastuzumab-containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243, 2012
15. Perez EA, Holmes E, De Azambuja E, et al: Disease-free survival (DFS) in the lapatinib alone arm and expanded results of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Ann Oncol 25:v1-v41, 2014 (suppl 5; abstr LBA7)
16. Telli ML, Hunt SA, Carlson RW, et al: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 25: 3525-3533, 2007
17. EwerMS, Lippman SM: Type II chemotherapyrelated cardiac dysfunction: Time to recognize a new entity. J Clin Oncol 23:2900-2902, 2005
18. Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916, 2010
19. Ezaz G, Long JB, Gross CP, et al: Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3:e000472, 2014